China Oncology Commercial Innovation Summit Highlights Industry Opportunities Amid Major Sector Shifts

Anti-cancer drugs are exempt from tariffs and subject to reduced value-added tax, with national centralized procurement and drug price negotiations set to launch soon; former Pfizer China General Manager Wu Xiaobin has joined BeiGene, an innovative oncology pharmaceutical company; the nine-valent HPV vaccine received approval in a record-breaking eight days...

Recent Major Developments in Oncology: What Do They Signify, and How Will They Impact the Industry’s Future?

The “China Oncology Business Innovation Summit,” held in Shanghai on May 27, will focus on discussing overall market opportunities in oncology, scouting for innovative unicorn companies, breakthroughs in oncology drug marketing models, upgrades in oncology treatment services, and major innovations in patient payment models.

Time: May 27, 2018, 9:00-18:00

Venue: Evergreen Laurel Hotel, Pudong New Area, Shanghai

Registration Link:http://www.huodongxing.com/event/3438423713600

Forum Topics: Innovation in Cancer Diagnosis and Early Screening, Innovation in Cancer Care Services, Support for Cancer Patients, Innovation in Cancer Payment Models, Investment Opportunities in the Oncology Industry

Target Audience: Oncologists, oncology pharmaceutical and diagnostic companies, medical device manufacturers, healthcare service providers, investors, and media

Conference Agenda:

The panelists for the roundtable discussion also include:

Founder of YiJiaYi

Founder of Yinuo Oncology

Founder of Bao Guanjia

Partner at Hillhouse Capital

Partner at Puhua Capital

General Manager of MSD China Oncology Division, etc.

Organizer: Liu Qian Marketing Studio

Co-organizers: VCBeat, Oncology News

Supported by: PharmCube, Caixin Health